Please use this identifier to cite or link to this item:
Title: Palliative Care Clinical Trials: Building Capability and Capacity.
Austin Authors: Philip, Jennifer;Le, Brian;Pasanen, Leeanne;Rosens, Evelien;Wong, Aaron ;Mendis, Ruwani;Boughey, Mark;Coperchini, Maria;Moran, Juli A ;Hynson, Jenny;Weil, Jenny;Rosenthal, Mark
Affiliation: Palliative Care Service, Royal Children's Hospital, Melbourne, Australia
Department of Palliative Care, St Vincent's Hospital Melbourne, Fitzroy, Australia
Victorian Comprehensive Cancer Centre, Australia
Palliative Care
Palliative Care Service, Western Health, Footscray, Australia
Department of Medicine, University of Melbourne, Fitzroy, Australia
Departments of Palliative Care and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
Departments of Palliative Care and Medical Oncology, Melbourne Health, Victorian Comprehensive Cancer Centre, Parkville, Australia
Issue Date: 2022
Date: 2021-11-17
Publication information: Journal of palliative medicine 2022; 25(3): 421-427
Abstract: Clinical trials are a key component of expanding the evidence base in palliative care. A key strategic objective of the Victorian Comprehensive Cancer Centre (VCCC), a multisite cancer center alliance, was to increase palliative care clinical trial expertise. The palliative care services within the VCCC alliance presented substantial trial development opportunities with large number of patients and established relationships, but few trial-active centers. Objectives: To establish a multi-site "Building Capability in Palliative Care Clinical Trials" program as a service development, and to assess the strategies, activities, and the outcomes resulting from this program. Methods: A series of strategies and activities were developed linked to the key program objectives of increasing the number of clinical sites and skilled clinicians conducting clinical trials, increasing the number of trials available and patients participating, broadening research opportunities in palliative care, and establishing the program sustainability. Results: In the two years of implementation, the program resulted in the establishment and conduct of several Phase 4 postmarketing pharmacovigilance studies, nine Phase 2 and 3 trials across five palliative care services, and a Phase 1 clinical trial. During the program, 150 patients were recruited to clinical trials, and 258 prospective pharmacovigilance monitoring cases were recorded. Five investigator-initiated trials were developed by clinical trial fellows and achieved competitive (n = 3) or commercial (n = 2) funding. Clinicians reported that undertaking clinical trials had increased attention to the evidence base of care provision, and increased service research activity more broadly. Long-term sustainability remains a challenge, particularly in the context of the COVID-19 pandemic. Conclusions: Clinical trials in palliative care services are feasible, acceptable, and result in increased attention to the evidence base of care. The strategies detailing the framework, activities, and outcomes have been collated to facilitate implementation of clinical trials in other sites and with other trial-naive disciplinary groups.
DOI: 10.1089/jpm.2021.0314
ORCID: 0000-0002-3312-0645
Journal: Journal of Palliative Medicine
PubMed URL: 34788568
Type: Journal Article
Subjects: clinical research
clinical trials
palliative care
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 28, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.